Innovative Therapies | Transforming Lives

Archive for the Kineta Press Release Category

Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa Fever

Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa Fever Phase 1 study to assess the safety, tolerability and pharmacokinetic profile of LHF-535 in healthy volunteers No therapy or vaccine currently approved for use in Lassa fever Seattle, WA, September 5, 2018 – Kineta,

Read more

Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech

Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech Collaboration to develop a first-in-class α9/α10 nicotinic acetylcholine receptor antagonist for the treatment of chronic pain Kineta to receive undisclosed upfront payment and up to $359 million in additional development and commercial milestones.

Read more

Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models

Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models Small molecule RIG-I agonist induces innate immune responses, immunogenic tumor cell death and in vivo protective immune responses in a colon carcinoma model Tumor regression also demonstrated in B16F10 melanoma model SEATTLE, WA, April 5,

Read more

Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference

Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference New data on Kineta’s small molecule RIG-I agonists in tumor models to be unveiled SEATTLE, WA, March 22, 2018 – Kineta Immuno-oncology, LLC, a biotechnology company focused on developing disruptive technologies

Read more

Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference

Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference SEATTLE, WA, January 22, 2018 – Kineta Immuno-oncology, LLC, a biotechnology company focused on developing disruptive technologies to turn cold tumors hot, today announced that they have been invited to present at the Immuno-Oncology

Read more

Kineta to Present at Symposium on Pandemic Preparedness

Kineta to Present at Symposium on Pandemic Preparedness LHF-535 Lassa fever antiviral and vaccine adjuvant program to be highlighted Seattle, WA, June 12, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced Kineta Vice President of R&D and Head of

Read more

Kineta to Present at Symposium on Next-Generation Therapeutics for the Treatment of Pain

Kineta to Present at Symposium on Next-Generation Therapeutics for the Treatment of Pain Seattle, WA, April 25, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced Kineta CEO Shawn Iadonato has been invited to present at the Next-Generation Therapeutics for

Read more

Kineta to Present at the Planet MicroCap Showcase 2017

Kineta to Present at the Planet MicroCap Showcase 2017 Seattle, WA, April 21, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced the company has been invited to present at the inaugural Planet MicroCap Showcase being held on April 26-28,

Read more

Kineta to Present at the 24th Annual Future Leaders in the Biotech Industry Conference

Kineta to Present at the 24th Annual Future Leaders in the Biotech Industry Conference New Advances in Chronic Pain Program to be Highlighted Seattle, WA, April 5, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced the company has been

Read more

Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model

Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model Small Molecule RLR Agonist induced immunogenic tumor cell death in study Seattle, WA, March 23, 2017 – Kineta, Inc., a biotechnology company focused on the translational development of novel therapies in immuno-oncology,

Read more
Page 1 of 3123